The present invention provides a simple and efficient method for synthesis of 4-[bis (2-chloroethyl)-amino]-L-phenylalanine hydrochloride. The process involves the treatment of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine free base with hydrochloric acid in water followed by isolation of 4-[bis(2-chloroethyl)-amino]-phenylalanine hydrochloride of desired purity.

The present invention provides a simple and efficient method for synthesis of 4-[bis (2-chloroethyl)-amino]-L-phenylalanine hydrochloride. The process involves the treatment of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine free base with hydrochloric acid in water followed by isolation of 4-[bis(2-chloroethyl)-amino]-phenylalanine hydrochloride of desired purity.

PURPOSE: A pharmaceutical composition containing 3-caffeoyl-4-dihydrocaffeoyl quinic acid(CDCQ) is provided to suppress cell basal lamina digesting enzyme MMP-2 and MMP-9 activities and prevent cancer cell metastasis. CONSTITUTION: A pharmaceutical composition for suppressing cancer metastasis contains 3-caffeoyl-4-dihydrocaffeoylquinic acid. The composition suppresses activity of MMP-2(matrix metalloprotease-2) or MMP-9(matrix metalloprotease-9). A health food for preventing metastasis contains...

Temperature sensitive immunoliposomes are provided to improve selectivity of drugs to target cells by binding an antibody recognizing an epitope specific to the target cell so that the drugs are transported to target cells such as cancer cells or target organs to kill cancer cells. Temperature-sensitive immunoliposomes consist of phospholipids of dipalmitoylphosphatidylcholine(DPPC) dimyristoylphosphatidylcholine(DMPC) and distearoylphosphatidylcholine(DSPC) and dioleoylphosphatidylethanolamine(...

The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.

Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which c...

Methods of treating preventing and/or managing cancer as well as and diseases and disorders associated with or characterized by undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy radiation therapy hormonal therapy biological therapy or immunotherapy which compris...

The present invention provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and bortezomib. The invention further provides a method for treating multiple myeloma in a subject, comprising the step of administering to the subject a combination of COMPOUND 1 and melphalan.

In the present invention there is disclosed a pharmaceutical composition containing cyclopeptide cyclo-(Arg-Gly-Asp-D-Phe-NMe-Val) and/or a physiologically acceptable salt thereof and at least one chemotherapeutic agent and/or physiologically acceptable salts thereof being selected from the group consisting of a) alkylating agents selected from a group consisting of busulfan carboplatin carmustine cisplatin cyclophosphamide dacarbazine ifosfamide and lomustine b) antibiotics selected from a grou...